Conference Details - Overview
Continuing Education Information
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 12.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses: Physicians’ Education Resource is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Physicians’ Education Resource provides up to 12.34 contact hours for completion of this educational activity.
Pharmacists: Physicians’ Education Resource is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education.
Universal Program Numbers: 0464-9999-10-001-L01-P (Practical Hematopathology-T-Cell Lymphomas – 0.30 CEUs), 0464-9999-10-002-L01-P (Leukemia Session – 0.35 CEUs), 0464-9999-10-003-L01-P (Bone Marrow Transplantation Workshop – 0.225 CEUs), 0464-9999-10-004-L01-P (Lymphoma Session – 0.4 CEUs).
Credits: up to 12.75 contact hours (1.275 CEUs)
To receive credit, participants must attend the entire session and complete Activity Evaluation and Record of Attendance forms. Statements of credit will be validated on-site upon completion of the program.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.
Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies
The Grove Park Inn Resort & Spa
Asheville, NC
April 9-11, 2010
Conference Overview
Overview and Purpose
The Duke Debates: Controversies in the Management of Hematologic Malignancies symposium is designed to provide updates on recent advances in and new data on the treatment and management of lymphoma, myeloma, and leukemia. Practical issues, current standards, and controversies in the management of these diseases will be discussed in debates, didactic lectures, and interactive case-based panel presentations. By linking a base of evidence from key clinical trials and authoritative guidelines to case-based applications and discussion of controversial issues, this activity will provide the participant with the tools to optimize decision making in order to improve patient outcomes.
Target Audience
This educational program is directed toward medical, surgical, and radiation oncologists; nurse practitioners; nurses; and pharmacists interested in the treatment of patients with hematologic malignancies. Fellows, physician assistants, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to attend.
Learning Objectives
At the conclusion of this symposium, you should be able to:
- Apply appropriate risk stratification measures to devise individualized treatment plans for patients with newly diagnosed leukemia, lymphoma, and myeloma
- Outline standard treatment options for patients with relapsed/refractory leukemia, lymphoma, and myeloma
- Evaluate the safety and efficacy of recent clinical advances in the management of patients with relapsed/refractory leukemia, lymphoma, and myeloma
- Debate the potential role of emerging novel agents for the treatment of patients with leukemia, lymphoma, and myeloma
- Recommend appropriate up-front or salvage hematopoietic stem cell transplantation for eligible patients with hematologic malignancies